Kelun Highlights First-Line Plans For Merck-Partnered Trop2 ADC

 
• By Dexter Jie Yan
first line treatment
1L treatment of EGFR-wild type NSCLC takes center stage in Kelun/Merck's plan for Trop2-targeting ADC • Source: Shutterstock

More from China

More from Focus On Asia